ArticleSouth Asian journal of cancer2025
The Effect of Topical Heparin Gel on Reducing Hand-Foot Syndrome Symptoms in Cancer Patients Treated with Capecitabine.
Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Hand-foot syndrome (HFS) is a distinct and relatively frequent toxic skin reaction associated with certain chemotherapy agents, particularly capecitabine. Given the complications of this syndrome and the critical importance of timely and accurate treatment, the present study aims to investigate the efficacy of topical heparin gel in alleviating HFS in cancer patients undergoing treatment with capecitabine. Methods: A total of 40 patients with grade ⩽ 1 HFS associated with capecitabine were randomly assigned to intervention and control groups. The intervention group received heparin sulfate gel four times a day (21 days) along with capecitabine treatment, while the control group received only capecitabine and placebo gel. The changes in the severity of HFS and clinical manifestations, including erythema, swelling, blisters, hyperkeratosis, and bleeding, at baseline and 3 weeks posttreatment were evaluated. The data were subsequently validated by Fisher's or Chi-square tests. Results: At the beginning of the study, there were no significant differences between the two groups regarding disease manifestations. However, after the intervention, a significant difference was observed between the groups in terms of erythema and swelling ( Conclusion: The management of HFS in cancer treatment includes a combination of prevention, patient education, symptom improvement, and dose-intensity management. According to the results, it can be said that due to the positive effect of topical heparin gel in improving HFS caused by capecitabine and due to the absence of side effects, the use of topical heparin gel is recommended. Key Points: Hand-foot syndrome (HFS) is a distinct and relatively frequent toxic skin reaction associated with capecitabine.The efficacy of topical heparin gel in alleviating HFS in cancer patients was investigated.Topical heparin gel is recommended due to its positive effect in improving HFS caused by capecitabine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.